Pregnyl 5000 Original 5000 IU Organon

Pregnyl 5000 Original 5000 IU Organon working principle and intake characteristics

Pregnyl 5000 Original 5000 IU Organon contains chorionic gonadotropin. This substance is secreted into the body of pregnant women through the placenta and has beneficial properties for athletes. It is used to eliminate the negative effects of the course of anabolic steroids.

Main positive properties of Pregnyl 5000 Original 5000 IU Organon

Gonadotropin triggers a number of processes in the body that help restore hormonal balance. Main effects:

• stimulates the production of sex hormones in the testes;
• prevents testicular atrophy;
• improves spermatogenesis.

In addition, under the influence of this substance, secondary sexual characteristics are more pronounced, and genitalia develop. After a course of steroids, which in most cases reduce testosterone production, this drug is considered the best.

Side effects

Since Pregnyl 5000 Original 5000 IU Organon triggers the active production of testosterone, the side effects can be the same as those of this hormone. These include gynecomastia, androgenic side effects, fluid accumulation in the tissues. Problems arise only when large doses are used, as well as with increased sensitivity to testosterone. In other cases, no side effects occur.

Recommendations for use

To use gonadotropin beneficially, you should choose the dosage individually. It is determined on the basis of the athlete’s testosterone tests, as well as the composition and duration of his last course of steroids, and can be up to 2000 IU.

The drug is administered by injection. This should be done no more than 2-3 times per week. The treatment can last 6 weeks or longer, but the duration can also be chosen individually. To evaluate its effectiveness, the athlete takes a special blood test and consults a doctor.

Before using gonadotropin, also consult to rule out contraindications.

List of references

1. Crowley WF Jr, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res. 1985;41:473-531.
2. Reame NE, Sauder SE, Case GD, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion in women with hypothalamic amenorrhea: evidence that reduced frequency of gonadotropin-releasing hormone secretion is the mechanism of persistent anovulation. J Clin Endocrinol Metab. 1985;61(5):851-858.
3. Maione L, Dwyer AA, Francou B, Guiochon-Mantel A, Binart N, Bouligand J, Young J. Genetics in Endocrinology: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. Eur J Endocrinol. 2018;178(6):R55-R80.
4. Liu J, Wu YT, Ning G, Zheng S, Wu S, Chen X, Huang HF. Mutations in GNRHR, TACR3, and KISS1R in Chinese women with idiopathic hypogonadotropic hypogonadism. Fertil Steril. 2013;99(2):472-477.
5. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, Lee H, Boepple P, Crowley WF Jr, Pitteloud N. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med. 2007;357(9):863-873.